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Abstract
Context: The incidences of both gastroesophageal reflux disease (GERD) and metabolic syndrome (MetS) have increased in recent
years, and it has been suggested that there is a probable association between the two. The aim of this review is to clarify whether or
not MetS is a risk factor for the incidence of GERD.
Evidence Aquisition: We searched the PubMed, ProQuest, Ovid, Science Direct, and Google Scholar databases up to February 2015
regarding the relationship between GERD and MetS as found in observational studies. Any studies that evaluated the association
between the components of MetS and GERD, as well as any studies examining the association of MetS with Barrett’s esophagus or
esophageal carcinoma, were excluded.
Results: Thirteen studies met the eligibility criteria. The results of nine studies suggested that there was a higher prevalence of
MetS among patients with GERD (P < 0.05) and, thus, it could be considered as an independent risk factor for the incidence of GERD.
However, in the one study was not observed significant association between GERD and MetS (P = 0.71). Two studies in which the
prevalence of GERD was compared between individuals with and without MetS showed a higher prevalence of GERD in patients with
MetS (P < 0.05). However, this finding was not observed in a similar study conducted among female participants, which reported
that the different types of MetS were not important factors with regard to the prevalence of erosive esophagitis (P = Not significant).
Conclusions: It can be concluded that MetS may increase the risk of GERD. Consequently, there might be potential benefits to treat-
ing the metabolic abnormalities in these patients.
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1. Context
Gastroesophageal reflux disease (GERD) is considered
to be a common and chronic digestive disease in the
United States and in Europe (1, 2). However, the prevalence
of GERD has been increasing in Asian countries in recent
decades (3, 4). An endoscopic survey conducted in Iran
showed the overall prevalence of reflux esophagitis in sub-
jects over 40-year-old with a general health status to be 37%
(5).
GERD is commonly characterized by an abnormal back-
ward flow of gastric contents into the esophagus, in which
esophagitis can occur as a result of the chronic exposure of
the esophagus epithelium to gastric acid, which can cause
esophageal mucosal injury, bleeding or ulcers (6-8). GERD
is generally considered to be classifiable into three cate-
gories: non-erosive esophagitis, erosive esophagitis, and
Barrett’s esophagus (9, 10). Aside from the most preva-
lent signs of GERD, namely heartburn and acid regurgi-
tation, there are some other reported symptoms, such as
eructation, nausea, sore throat, cough, and chest pain (2,
11). High intra-abdominal pressure, elevated gastric acid
production, and abnormal relaxation of the esophageal
sphincter can also play an important role in the develop-
ment of the disease (1, 6). Several risk factors, including old
age, male gender, race, family history, obesity, hiatal her-
nia, smoking, and alcohol consumption, have been iden-
tified for GERD (12-14). As the long-term complications of
GERD can reduce patients’ health-related quality of life
and increase their healthcare costs (5, 15), more attention
is needed to control the GERD-related risk factors.
On the other hand, metabolic syndrome (MetS) is con-
sidered to be a major metabolic disorder worldwide. The
prevalence of MetS is estimated to be approximately 24%
in the United States, 12% in Europe, and 10% to 40% in most
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Asian countries (16, 17). MetS is diagnosed if three or more
of the following five medical conditions are met: elevated
waist circumference (WC) (≥ 90 cm for men and≥ 80 cm
for women), high serum triglycerides (TG) (≥ 150 mg/dL),
low levels of high density lipoprotein cholesterol (HDL-C)
(< 40 mg/dL in males and < 50 mg/dL in females), elevated
blood pressure (BP)) systolic≥ 130 mmHg and/or diastolic
≥ 85 mmHg, (and increased fasting blood glucose (FBG)
(≥ 100 mg/dL) (18, 19). It has been suggested that visceral
adiposity, hypertension, hyperglycemia, and dyslipidemia
can all lead to insulin resistance. Thus, patients with MetS
are at risk of insulin resistance as well as GERD. As previ-
ously mentioned, obesity is one of the common risk fac-
tors for GERD (9, 20, 21). According to recent evidence, the
incidences of both diseases have been rapidly increasing.
Hence, a possible relationship has been hypothesized be-
tween MetS and GERD (22). Most studies focusing on the
association of obesity with GERD have revealed that obe-
sity can lead to a significant increase in the risk of devel-
oping GERD symptoms (23-27). Although several studies
have indicated that each criterion of MetS (i.e., abdominal
obesity, hyperglycemia, and hypertension) is a risk factor
for reflux esophagitis, the relationship between MetS as a
whole entity and the occurrence of GERD has not been ex-
tensively studied (28-32). Indeed, only a limited number
of studies have been performed to determine whether or
not MetS can be considered as a risk factor for GERD (20,
22, 33-39). Furthermore, the accumulated evidence regard-
ing their association has not yet been comprehensively re-
viewed.
1.1. Objectives
We conducted the present systematic review in order
to better understand the association between MetS and
GERD by focusing on the prevalence of MetS among pa-
tients with GERD. With regard to the importance of this
study, if it is determined that MetS is able to influence the
severity and incidence of GERD, treating and relieving the
factors potentially involved in MetS may prove a successful
medical intervention for alleviating GERD. Finally, treating
MetS and changing people’s lifestyles may alleviate GERD
and reduce the incidence of more serious complications
such as Barrett’s esophagus and esophagus cancer.
2. Evidence Aquisition
2.1. Search Strategy
We used the PRISMA (preferred reporting items for sys-
tematic reviews and meta-analyses) statement to review
all articles assessing the association between MetS and
the occurrence of GERD. We searched the PubMed, Pro-
Quest, Ovid, Science Direct, and Google Scholar databases
up to February 2015. As seen in Table 1, which presents the
search strategy used to identify the included articles, key-
words relevant to the MetS or GERD sections were linked
using “OR” as a Boolean function, and the results of the
two sections were combined by utilizing “AND”. The search
keywords were: (“gastroesophageal reflux” OR “gastro-
esophageal reflux” OR “gastro-oesophageal reflux” OR “e-
sophageal reflux” OR “reflux esophagitis” OR “non-erosive
esophagitis” OR “erosive esophagitis”) AND (“metabolic
syndrome” OR “insulin resistance” OR “abdominal obesi-
ty” OR “hyperglycemia” OR “hyperlipidemia” OR “hyper-
tension” OR “waist circumference”). We did not use any
language or time restrictions in our literature search. The
search results from the different databases were combined
using EndNote X7 software and any duplicates were re-
moved. An initial screening of the articles’ titles and ab-
stracts to exclude irrelevant studies was independently de-
veloped by two investigators in separate places so as to
guarantee the blindness of the search. Then, the full texts
of the remaining articles were examined to determine the
eligible studies. A kappa coefficient of 0.78 was used as a
measurement of the agreement between the identification
and selection of articles. Finally, the results were merged
and any differences were resolved by the third investiga-
tor. Furthermore, we screened the reference lists of the se-
lected articles in order to identity additional relevant arti-
cles (Figure 1).
2.2. Eligibility Criteria
The inclusion criterion for articles selected for review
were those studies that evaluated the association between
MetS and the occurrence of GERD. Studies were excluded
based on any of the following criteria: animal or in vitro
studies; studies that only evaluated the relationship be-
tween the components of MetS and GERD and did not re-
port any related data on the prevalence of MetS in patients
with GERD; and studies that investigated the association of
MetS with either Barrett’s esophagus or esophageal adeno-
carcinoma.
2.3. Data Extraction and Quality Assessment
After the two independent researchers had assessed
the details of the final eligible studies, a third assessment
was performed by another investigator to ensure a final
high quality evidence-based analysis. We abstracted the
following data from the included papers: first author’s
name, publication year, place of publication, study design,
definition of case and control subjects, sample size, mean
age, results, and study quality.
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Table 1. Search Strategy
Search Engines Search Keywords Number of Search Results
PubMed
- Component 1: Gastroesophageal reflux (gastro-esophageal reflux [tiab]) OR (gastroesophageal reflux
[tiab]) OR (gastro-oesophageal reflux [tiab]) OR (esophageal
reflux [tiab]) OR (reflux esophagitis [tiab]) OR (non-erosive
esophagitis [tiab]) OR (erosive esophagitis [tiab])
21,358
- Component 2: Metabolic syndrome (metabolic syndrome [tiab]) OR (insulin resistance [tiab]) OR
(abdominal obesity [tiab]) OR (hyperglycemia [tiab]) OR
(hyperlipidemia [tiab]) OR (hypertension [tiab]) OR (Waist
Circumference [tiab])
399,827
- Component 1 and Component 2: Gastroesophageal reflux
and Metabolic syndrome
(gastro-esophageal reflux [tiab]) OR (gastroesophageal reflux
[tiab]) OR (gastro-oesophageal reflux [tiab]) OR (esophageal
reflux [tiab]) OR (reflux esophagitis [tiab]) OR (non-erosive
esophagitis [tiab]) OR (erosive esophagitis [tiab]) AND (metabolic
syndrome [tiab]) OR (insulin resistance [tiab]) OR (abdominal
obesity [tiab]) OR (hyperglycemia [tiab]) OR (hyperlipidemia
[tiab]) OR (hypertension [tiab]) OR (Waist Circumference [tiab])
416
ProQuest
- Component 1: Gastroesophageal reflux ab((gastro-esophageal reflux) OR (gastroesophageal reflux) OR
(gastro-oesophageal reflux) OR (esophageal reflux) OR (reflux
esophagitis) OR (non-erosive esophagitis) OR (erosive
esophagitis))
4739
- Component 2: Metabolic syndrome ab((metabolic syndrome) OR (insulin resistance) OR (abdominal
obesity) OR (hyperglycemia) OR (hyperlipidemia) OR
(hypertension) OR (Waist Circumference))
100,258
- Component 1 and Component 2: Gastroesophageal reflux
and Metabolic syndrome
ab((gastro-esophageal reflux) OR (gastroesophageal reflux) OR
(gastro-oesophageal reflux) OR (esophageal reflux) OR (reflux
esophagitis) OR (non-erosive esophagitis) OR (erosive
esophagitis)) AND ab((metabolic syndrome) OR (insulin
resistance) OR (abdominal obesity) OR (hyperglycemia) OR
(hyperlipidemia) OR (hypertension) OR (Waist Circumference))
161
Ovid
- Component 1: Gastroesophageal reflux (Gastro-esophageal reflux OR gastroesophageal reflux OR
gastro-oesophageal reflux OR esophageal reflux OR reflux
esophagitis OR non-erosive esophagitis OR erosive esophagitis).
ab.
26,941
- Component 2: Metabolic syndrome (Metabolic syndrome OR insulin resistance OR abdominal obesity
OR hyperglycemia OR hyperlipidemia OR hypertension OR Waist
Circumference). ab.
502,592
- Component 1 and Component 2: Gastroesophageal reflux
and Metabolic syndrome
((gastro-esophageal reflux OR gastroesophageal reflux OR
gastro-oesophageal reflux OR esophageal reflux OR reflux
esophagitis OR non-erosive esophagitis OR erosive esophagitis)
and (metabolic syndrome OR insulin resistance OR abdominal
obesity OR hyperglycemia OR hyperlipidemia OR hypertension
OR Waist Circumference)). ab.
607
Science Direct
- Component 1: Gastroesophageal reflux TITLE((gastro-esophageal reflux) OR (gastroesophageal reflux) OR
(gastro-oesophageal reflux) OR (esophageal reflux) OR (reflux
esophagitis) OR (non-erosive esophagitis) OR (erosive
esophagitis))
48,354
- Component 2: Metabolic syndrome TITLE ((metabolic syndrome) OR (insulin resistance) OR
(abdominal obesity) OR (hyperglycemia) OR (hyperlipidemia) OR
(hypertension) OR (Waist Circumference))
41,946
- Component 1 and Component 2: Gastroesophageal reflux
and Metabolic syndrome
TITLE ((gastro-esophageal reflux) OR (gastroesophageal reflux) OR
(gastro-oesophageal reflux) OR (esophageal reflux) OR (reflux
esophagitis) OR (non-erosive esophagitis) OR (erosive
esophagitis)) and TITLE((metabolic syndrome) OR (insulin
resistance) OR (abdominal obesity) OR (hyperglycemia) OR
(hyperlipidemia) OR (hypertension) OR (Waist Circumference))
210
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Databases Search (n = 1394)
121  Conducted in Animals or In vitro 
436  Unrelated Studies
Duplicate Studies Excluded (n = 779)
Manual Search Through Related Articles (n= 3)
 
Full - Text Articles Assessed (n = 58)
Full - Text Articles Excluded (n = 48)  
31 Evaluating the Association Between 
the Components of Metabolic  
Syndrome and GERD 
1 5 Evaluating the Association of 
Metabolic Syndrome with Barrett's 
Esophagus or Esophageal Carcinoma
2 Review Articles  
Studies Included in the  
Systematic Review (n = 13)
 
Titles and/or abstracts excluded (n=557)
Figure 1. Flow Chart Representing the Study’s Selection Process
We used the previously validated nine-point
Newcastle-Ottawa scale (NOS), a method for elevating
the methodological quality of non-randomized studies
such as case-control and cohort studies, to score the in-
cluded observational articles (40, 41). The three major
components of the NOS scoring technique are: selection
of participants (maximum score = 4*), comparability of
study groups (maximum score = 2*), and measurement
of the outcome or exposure (maximum score = 3*). High
quality studies were considered to have a total of seven or
more points, while low quality studies were considered to
have less than seven points. The maximum score was nine
points, which could represent the highest quality of study.
3. Results
Our initial database search retrieved 1394 reports. Af-
ter an initial screening of titles and abstracts, 58 articles
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were reviewed against the eligibility criteria. Eventually,
ten observational studies were included in the final anal-
ysis, and three additional papers were selected by hand af-
ter screening the reference lists of the articles. We excluded
the remainder of the articles, including the review articles
(n = 2) and those that either evaluated the association be-
tween the individual components of MetS and GERD (n =
31) or the association of MetS with Barrett’s esophagus or
esophageal carcinoma (n = 15). All of the 13 included stud-
ies were conducted in Asian countries, and they were either
case-control or cross-sectional studies. A total of 23,687
participants aged 37- to 60-year-old were included in these
studies. The average quality score of the included articles
was 6.5 points. Six of them were classified as high quality
articles (22, 30, 31, 33, 34, 39), while the remaining seven
studies were classified as low quality (20, 32, 37, 42-45). In-
formation regarding the characteristics of the articles and
the participants, the methodological quality of the arti-
cles, and the outcome measures of the articles is collected
in Tables 2 and 3.
Most of the previous research studies focused on the
various risk factors of GERD, including the components of
MetS, obesity, and smoking. In some of these studies, the
prevalence of MetS as a whole entity and as an independent
risk factor for GERD, in addition to the assessment of the
relationship between the individual components of MetS
and GERD, were investigated. Further, in a few studies, the
prevalence of GERD in patients with MetS was been com-
pared with that in subjects without MetS. We reviewed all
of the related studies that focused on the association be-
tween MetS and GERD. The outcomes of and differences be-
tween the selected studies will now be summarized in de-
tail.
3.1. The Prevalence of MetS in Patients with GERD
Several studies were conducted in a Taiwanese popu-
lation to evaluate the association between metabolic risk
factors such as MetS rate, body mass index (BMI), WC, BP,
lipid profile, and blood glucose and the severity of erosive
esophagitis in patients with and without erosive esophagi-
tis. Chua et al. (31) observed that there was a significant in-
crease in the measurements of BMI, WC, BP, and TG, as well
as a significant decrease in low density lipoprotein choles-
terol (HDL-C) levels, among patients with erosive esophagi-
tis (P < 0.05 for all). They reported that the prevalence of
MetS in patients with erosive esophagitis was 27.8%, while
in the control group it was 17.8%. Chua et al. (31) also re-
vealed that MetS was significantly associated with a higher
risk of reflux esophagitis (Odds ratio [OR]: 1.76, 95% confi-
dence interval [CI]: 1.27 - 2.44, P = 0.001). Similar findings
were also reported in a study by Hsu et al. (42). They found
that there was a significant positive association between
the prevalence of MetS and erosive esophagitis (OR: 1.6, 95%
CI: 1.04 - 2.45, P = 0.03). Indeed, they showed that the preva-
lence of MetS was higher in patients with erosive esophagi-
tis than in the control group (28.2% vs. 19.8%). In addition,
certain risk factors such as old age, male sex, smoking, al-
cohol consumption, elevated FBG and BP, and higher levels
of LDL-C and TG, led to an increasing prevalence of erosive
esophagitis (P < 0.05 for all) (42). On the other hand, Tai
et al. (45) compared the prevalence of MetS in obese pa-
tients with and without erosive esophagitis. They revealed
that although obese patients with erosive esophagitis had
a higher prevalence of MetS than patients without erosive
esophagitis, no significant differences were observed be-
tween them (75.0% vs. 63.6%, P = 0.07). Indeed, they con-
cluded that the presence of MetS was not associated with
a higher prevalence of erosive esophagitis (OR: 1.13, 95% CI:
0.6 - 2.13, P = 0.71). However, increased WC (P < 0.01) and in-
sulin resistance (P = 0.02), as well as the presence of reflux
symptoms (P = 0.01), were independent risk factors associ-
ated with erosive esophagitis (45).
Chung et al. also assessed the association of MetS and
visceral obesity with reflux esophagitis among 7078 Kore-
ans who were referred for a health check-up (30). Follow-
ing endoscopic examination, 3539 subjects with a diagno-
sis of erosive esophagitis were compared with individuals
without erosive esophagitis as a control group. After ad-
justment for age and sex, the results suggested that smok-
ing, alcohol consumption, and each of the components of
MetS were significant risk factors for reflux esophagitis (P
< 0.001 for all). Moreover, they reported that the preva-
lence of MetS in patients with reflux esophagitis was sig-
nificantly higher than in those without reflux esophagitis
(26.9% vs. 18.5%, P < 0.001), concluding that MetS could
increase the risk of reflux esophagitis after a multivariate
analysis (OR: 1.42, 95% CI: 1.26 - 1.60, P < 0.001).
On the other hand, Kallel et al. (32) used a 24-hour pH-
metry monitoring method for GERD diagnosis, and they re-
ported that 54 out of 100 individuals were diagnosed with
pathological acid GERD. The multivariate regression anal-
ysis in their study revealed that higher measurements for
WC (P = 0.002) and glucose levels (P = 0.001) were consid-
ered to be significant risk factors for GERD. In addition, de-
spite the higher BMI ranges in patients with GERD com-
pared to the control group, BMI could not be considered
as an independent risk factor for GERD (P = 0.42). More-
over, the prevalence of MetS was higher in patients with
GERD than in individuals without GERD (50% vs. 19.56%; P
= 0.002), and after adjusting the age, sex, and BMI values,
MetS was considered to be an independent factor associ-
ated with a 2.82-fold increase in risk of GERD (95%CI: 1.08
- 7.35, P = 0.03).
In another cross-sectional and case-control study (34),
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Table 2. Basic Characteristics of the Included Studies (Prevalence of MetS)
Study
(Year)
Country Study
Design
Time
Pe-
riod
Definition of Case
and Control
Sample Size Mean Age
(Year)
Patients with MetS P
Value
OR (95% CI) P
Value
Adjusted
Factors
Study
Score
Keywords
Case
(M/F)
Control
(M/F)
Case,
No.
(%)
Control,
No.
(%)
Chua et
al. (2009)
(31)
Taiwan Retrospective
case-
control
2004-
2006
Case: Patients with
EE; Control: Healthy
individuals without
EE
427
(365/62)
427
(365/62)
48.3 118
(27.6)
76
(17.8)
NR 1.76
(1.27–2.44); P =
0.00
Age, gender 7 Erosive esophagitis,
metabolic syndrome,
reflux esophagitis
Chung et
al. (2008)
(30)
South
Ko-
rea
Cross-
sectional
case-
control
2004-
2007
Case: Patients with
RE; Control: Healthy
individuals without
RE
3539
(2810/729)
3539
(2810/729)
47.6 26.9 % 18.5% P <
0.00
1.42
(1.26-1.60); P <
0.00
Age, gender
smoking,
alcohol, BMI
8 NM
Kallel et
al. (2011)
(32)
Tunisia Cross-
sectional
2009 Case: Patients with
GERD; Control:
Healthy individuals
without GERD
54;
Total:
3/67
46;
Total:
33/67
Case: 44.5;
Control
37.6
50% 19.56% P =
0.00
2.82
(1.08–7.35); P =
0.03
Age, gender
BMI
6 Body mass index,
DeMeester score,
gastroesophageal
reflux,metabolic
syndrome, pH-metry,
waist circumference
Wu et al.
(2011) (22)
China Case-
control
2010 Case: Patients with
RE; Control: Healthy
individuals without
RE
182(82/100) 190
(93/97)
Case: 46.2;
Con-
trol47.2
55
(30.2)
40
(21.1)
P =
0.06
2.01 (1.15-3.50);
P = 0.01
Age, gender 8 Metabolic syndrome,
reflux esophagitis
Loke et
al. (2013)
(34)
Taiwan Cross-
sectional
case-
control
2008 Case: Patients with
EE; Control:
individuals without
EE
507
(419/88)
507
(419/88)
51.2 239
(47.1)
191
(37/7)
P <
0.00
1.47 (1.14-1.89);
P = 0.00
Age, gender 7 Erosive esophagitis,
metabolic syndrome,
central obesity,
abnormal liver function,
dyslipidemia
Park et al.
(2008)
(20)
South
Ko-
rea
Cross-
sectional
case-
control
2006 Case: Patients with
EE; Control: Healthy
individuals without
EE
1679
(86% /
14%)
3358
(59%/41%)
45.2 353 (21) 433
(13)
P <
0.00
1.25
(1.04-1.49); P =
0.01
Age 6 Metabolic syndrome,
erosive esophagitis,
insulin resistance, fatty
liver
Hsu et al.
(2011) (42)
Taiwan Cross-
sectional
2007 Case: Patients with
EO; Control: Healthy
individuals without
EO
131
(88/43)
612
(255/357)
Case: 53.6;
Control
51.3
37
(28.2)
121
(19.8)
NR 1.60
(1.04–2.45); P
= 0.03
None 5 NM
Tai et al.
(2010)
(45)
Taiwan Cross-
sectional
2007-
2009
Case: Obese patients
with EE; Control:
Obese patients
without EE
84
(41/43)
176
(56/120)
Case: 32.1;
Con-
trol31.2
63
(75.0)
112
(63.6)
P =
0.07
1.13
(0.60–2.13); P
= 0.71
Age 6 NM
Niigaki et
al. (2013)
(43)
Japan Cross-
sectional
2010-
2011
Case: Patients with
GERD or RE; Control:
Healthy individuals
without GERD or RE
3775 52 477
(12.6)
NM RE: 2.21
(1.63–3.00); P
< 0.00, GERD:
1.8 (1.46–2.39);
P < 0.00
NM 5 Metabolic syndrome,
obesity, reflux
esophagitis,
gastroesophageal reflux
disease
Leeet al.
(2009)
(33)
Taiwan Cross-
sectional
2003-
2006
Case: Patients with
MetS, erosive or
non-erosive reflux
disease; Control:
Patients without
MetS and with
erosive or
non-erosive reflux
disease
3669 56.3 498
(13.6)
NM a 1.75
(1.29-2.38); P <
0.05
Gender,
smoking,
short-term
use of PPI or
H2RA
7 NM
Abbreviations: BMI, body mass index; CI, confidence interval; EE, erosive esophagitis; EO, erosive oesophagitis; GERD, gastroesophageal reflux disease; F, female; M, male; MetS, metabolic syndrome; NM, not mentioned; NR, not reported;
OR, odds ratio; RE, reflux esophagitis.
a Relative risk of progression from non-erosive to erosive state in patients with MetS.
5015 patients underwent an upper endoscopy. A total
of 507 patients with erosive esophagitis and 507 nor-
mal individuals as the control group were selected and
matched according to age and gender. Several factors
such as BMI, liver enzymes, and the components of
MetS were assessed. The levels of BMI, WC, BP, aspar-
tate amino transferase/glutamate oxaloacetate transam-
inase (AST/GOT) and alanine amino transferase /gluta-
mate pyruvate transaminase (ALT/GPT), FBG, BP, and TG, as
well as the ratios of total cholesterol (TC)/HDL-C and LDL-
C/HDL-C, were significantly higher in patients with erosive
esophagitis compared with the controls, while the HDL-C
levels were lower in the case group. Univariate and mul-
tivariate logistic regression analysis in this study showed
that central obesity, hypertension, hyperglycemia, hyper-
triglyceridemia, TC/HDL-C > 5, AST > 37 U/L, and ALT > 40
U/L could be significantly associated with a higher proba-
bility of developing erosive esophagitis (P < 0.05 for all).
Loke et al. (34) observed that the prevalence of MetS
was significantly higher in patients with erosive esophagi-
tis than in normal individuals (47.1% vs. 37.7%; P < 0.005),
and also that they had a higher risk of reflux esophagitis
(OR: 1.47, 95%CI: 1.14 - 1.89, P = 0.003).
One other study was conducted to determine whether
MetS and insulin resistance were risk factors for the devel-
opment of erosive esophagitis (20). Some 1679 individuals
out of 4206 subjects who had been referred to the medical
screening center in South Korea between January and De-
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Table 3. Basic Characteristics of the Included Studies (Prevalence of GERD)
Study
(Year)
Country Study
Design
Time
Pe-
riod
Definition of Case
and Control
Sample Size Mean age
(Year)
Patients with GERD P
Value
OR (95%
CI); P
Value
Adjusted
Factors
Study
Score
Keywords
Case
(M/F)
Control
(M/F)
Case,
No. (%)
Control,
No. (%)
Hirata et
al. (39)
(2012)
Japan Cross-
sectional
2009-
2011
Case: T2DM patients
with MetS; Control:
T2DM patients
without MetS
28
(9/19)
38
(18/20)
Case: 67;
Control 63
a 18/10 33/5 P =
0.03
NR Age, gender 7 Gastroesophageal
reflux symptom,
metabolic syndrome,
visceral fat,
adiponectin
Sogabe et
al. (37)
(2014)
Japan Cross-
sectional
2008-
2013
Case: Women with
V-type MetS; Control:
Women without
S-type MetS
50 F 404 F Case: 54.9;
Control
58.7
6 (12) 45 (11.1) P =
NS
NR NM 6 NM
Sogabe et
al. (44)
(2012)
Japan Cross-
sectional
2008-
2009
Case: Men with V-type
MetS; Control: Men
without S-type MetS
145 M 120 M Case: 56.1;
Control
57.9
41
(28.3)
14 (11.7) P <
0.01
3.80
(1.71-8.47);
P < 0.00
NM 6 Erosive esophagitis,
metabolic syndrome,
subcutaneous
fat-type, metabolic
syndrome,
ultrasonography,
visceral fat-type
metabolic syndrome
Abbreviations: CI, confidence interval; GERD, gastroesophageal reflux disease; F, female; M, male; MetS, metabolic syndrome; NM, not mentioned; NR, not reported; NS, not significant; OR, odds ratio; S-type, subcutaneous type; T2DM,
type 2 diabetes mellitus; V-type, visceral type.
a Frequency scale for the symptoms of GERD (FSSG) scores < 8 /≥ 8.
cember 2006 with erosive esophagitis were chosen as the
case group, while 3358 subjects with normal endoscopy re-
sults and no reflux symptoms were selected for the control
group. The groups were only matched for age. After com-
paring the levels of WC, BP, TG, and insulin resistance, as
well as the rate of fatty liver, between the two groups, the
results showed that all of these factors were significantly
higher among patients with erosive esophagitis, which
could be related to the increased risk of erosive esophagi-
tis (P < 0.001, P = 0.047, P = 0.003, P = 0.011, P < 0.001,
respectively). Moreover, the results of a multiple logistic
regression analysis demonstrated that the prevalence of
MetS was higher among patients with erosive esophagitis
than in the control group (21% vs. 12%; P < 0.001), with a sig-
nificant odds ratio for the risk of erosive esophagitis (OR:
1.25, 95% CI: 1.04 - 1.49, P = 0.01). Hence, there was a sig-
nificant association between MetS and erosive esophagitis.
In addition, comparing the severity of erosive esophagitis
according to the Los Angeles (LA) classification suggested
that MetS was significantly associated with a higher sever-
ity of erosive esophagitis. Thus, it could be considered as a
predictive factor for erosive esophagitis (P for linear trend
= 0.001).
In a study by Wu et al. (22), 182 patients with reflux
esophagitis who were diagnosed by an upper endoscopy
were selected as the case group, while 190 subjects with
normal endoscopy results were randomly selected as the
control group and then matched for age and gender with
the cases. It was observed that the levels of FBG and WC
and the waist to hip ratio (WHR) were significantly higher
among patients with reflux esophagitis compared with the
control group (P < 0.05 for all). A positive dose-response
relationship was seen between the prevalence of reflux
esophagitis and WHR (P < 0.01), TG (P = 0.02), and FBG (P
= 0.02), while an inverse dose-response relationship was
observed between reflux esophagitis and the levels of HDL-
C (P = 0.02) in male individuals. The assessment of MetS
rates revealed that although there were no significant dif-
ferences in the prevalence of MetS between the two groups
(30.2% vs. 21.1%; P = 0.06), there was a significant positive
association between MetS and reflux esophagitis (OR: 2.01,
95% CI: 1.15 - 3.50, P = 0.01).
Another study, which was conducted in a Japanese pop-
ulation between April 2010 and March 2011, included 3775
adults who had been referred to a medical center for their
routine annual health check-ups (43). 320 patients with
reflux esophagitis and 604 patients with GERD were diag-
nosed by either endoscopic examination, the criterion of a
QUEST score of ≥ 6, or their latest medical treatment for
GERD. The presence of MetS was also observed in 477 of the
study population. The multiple logistic regression analy-
sis used to identify the independent risk factors associated
with the presence of reflux esophagitis and GERD showed
that specific factors such as male sex (P < 0.0001), the pres-
ence of hiatal hernia (P < 0.0001), gastric mucosal atrophy
(P < 0.0001), visceral fat accumulation (P = 0.001), and dys-
lipidemia (P = 0.02) were significant predictive factors for
the presence of both diseases. In addition, it was observed
that the presence of MetS was considered to be a signifi-
cant risk factor for the prevalence of both reflux esophagi-
tis (OR: 2.21, 95% CI: 1.63 - 3.00, P < 0.0001) and GERD (OR:
1.871, 95% CI: 1.463 - 2.393, P < 0.0001), and it could also ag-
gravate the reflux symptoms in patients with or without re-
flux esophagitis.
The role of several metabolic risk factors in the devel-
opment of GERD has been assessed among 19,812 normal
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individuals (33). Subjects with MetS and non-erosive or
erosive esophagitis were identified by repeated upper en-
doscopy and selected for the case group (n = 3669) based
on the severity of their esophagitis (non-erosive or erosive)
according to the LA classification. Within three consecu-
tive study periods, 12.2%, 14.9%, and 17.9% of non-erosive
cases, respectively, progressed to the erosive esophagitis
stage, while 42.5%, 37.3%, and 34.6% of patients with ero-
sive esophagitis, respectively, regressed to the non-erosive
stage. The results obtained from the multivariate analy-
sis revealed that particular factors such as male sex, BMI
≥ 27, smoking, and heavy drinking could independently
increase the likelihood of progression from non-erosive to
erosive esophagitis, along with reducing the likelihood of
disease regression (P < 0.05 for all). Furthermore, it was
shown that the short-term use of acid suppressants could
increase the probability of regression of erosive esophagi-
tis to the non-erosive stage (P < 0.05). Moreover, MetS was
shown to be significantly associated with the progression
of the disease to erosive esophagitis, which could indicate
that patients with MetS have a significant risk of erosive
esophagitis (relative risk [RR]: 1.75, 95% CI: 1.29 - 2.38, P <
0.05).
3.2. The Prevalence of GERD in Patients with MetS
Hirata et al. (39) conducted a cross-sectional study
to determine the association of visceral fat accumula-
tion, adiponectin, and MetS with GERD symptoms in 66
Japanese individuals with type 2 diabetes. The frequency
scale for the symptoms of GERD (FSSG) questionnaire was
used to evaluate the reflux symptoms in patients with
GERD. Patients were considered to be positive if their FSSG
scores were eight or above. Bioelectrical impedance analy-
sis was used to measure the visceral fat area of the included
patients. In addition, subjects with MetS were also diag-
nosed according to the Japanese guidelines for MetS. The
results revealed that there were no significant differences
in age and gender between the group with MetS (n = 38)
and the without MetS (n = 28). Comparing the FSSG score,
anthropometry, and laboratory outcomes between the two
groups showed that the prevalence of the FSSG score≥ 8 (P
= 0.03), the mean values of the FSSG score (P = 0.01), BMI (P
= 0.002), WC (P = 0.016), TG (P = 0.011), and BP (P = 0.009)
were substantially higher among type 2 diabetic patients
with MetS than in patients without MetS. Moreover, these
findings indicated that there was a multiplicative effect on
the GERD symptoms score followed by the coexistence of
MetS and low levels of serum adiponectin (P = 0.04).
In two cross-sectional studies conducted by Sogabe et
al. (37, 44), the association between the different types
of MetS and erosive esophagitis in Japanese men and
women with MetS was investigated. Indeed, a question
was posed regarding whether or not there was a differ-
ence in the prevalence of erosive esophagitis between pa-
tients with the visceral fat type MetS (V-type MetS) and pa-
tients with the subcutaneous fat type MetS (S-type MetS).
The studies’ participants consisted of 454 women and 265
men with MetS who underwent a certain health check-up.
Comparing the prevalence of erosive esophagitis between
the women with V-type MetS and the women with S-type
MetS showed that there were no significant differences
between the two groups. More precisely, the logistic re-
gression analysis illustrated that hiatal hernia (P < 0.001),
hemoglobin A1c (HbA1c) (P < 0.05), and the presence of H.
pylori (P < 0.005) could be considered as significant pre-
dictors of the prevalence of erosive esophagitis in women
with MetS, whereas the types of MetS were not found to
be important factors in the prevalence of erosive esophagi-
tis. However, the study that was conducted among men
showed that the frequency of erosive esophagitis was sig-
nificantly higher in patients with V-type MetS than in pa-
tients with S-type MetS. Further, according to the logistic
regression analysis, the V-type MetS (OR: 3.80, 95% CI: 1.71 -
8.47, P < 0.005) was found to be a remarkable predictor of
the increased prevalence of erosive esophagitis, as was the
presence of hiatal hernia (P < 0.001).
4. Discussion
The present systematic review was performed to pro-
vide a comprehensive overview of the evidence on the asso-
ciation between MetS and GERD occurrence. In this study,
MetS has been considered and studied as a whole entity,
which can be seen as an innovation.Regarding the asso-
ciation between MetS and GERD, only two studies failed
to show any significant results (37, 45), while the rest of
the studies reported a strong relationship between the two
conditions (20, 22, 30-34, 39, 42-44). Generally, the results
showed that there could be a bidirectional relationship be-
tween MetS and GERD, which means that a higher preva-
lence of MetS might lead to a higher prevalence of GERD
and, conversely, that a higher prevalence of GERD might
lead to a higher prevalence of MetS. However, the exact
prevalence of MetS in patients with GERD varied in the re-
viewed studies, which might be due to differences in sex
distribution, race, age, and the methods used to diagnose
GERD and MetS. Moreover, the results demonstrated that
the prevalence of erosive esophagitis in men with MetS was
higher in patients with V-type MetS than in patients with S-
type MetS, while no relationships were reported between
erosive esophagitis and the types of MetS in women with
MetS (37, 44), which could be due to the greater accumula-
tion of visceral fat in men compared to the accumulation
of subcutaneous fat in women (29). Many other studies
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have also reported some significant positive associations
between GERD and its other risk factors, including the indi-
vidual components of MetS, obesity, hiatal hernia, insulin
resistance, smoking, and alcohol consumption (20, 22, 30-
34, 37, 39, 42-45). It is believed that MetS and GERD might
have a common pathogenesis (22). Although the precise
mechanism of the higher prevalence of GERD among pa-
tients with MetS remains unclear (43), several mechanisms
showed a few associations between each component of
MetS and the prevalence of GERD. Results have shown that
elevated WC, expressed as central, abdominal or visceral
obesity, could independently increase the risk of GERD
(20, 30, 31, 33, 34, 42, 43, 45). Indeed, as abdominal obe-
sity significantly caused metabolic abnormalities, it could
also contribute to the development of GERD (29, 46). Pre-
vious meta-analysis studies corroborated this finding, re-
porting that central adiposity could be strongly associated
with esophageal inflammation and reflux esophagitis (47).
Moreover, several studies observed that high BMI ranges,
representing obesity, could increase the risk of GERD (31,
33, 34, 42). However, conflicting results have been reported
in other studies, suggesting that no significant differences
were observed in BMI ranges among patients with or with-
out GERD (22, 30, 32, 45). Regarding the relationship be-
tween GERD and high BMI ranges, most of the studies have
reported that a significant association might exist between
the two (23, 25, 48, 49), although some studies have re-
vealed that BMI status could not be a predictive factor for
the development of GERD, but abdominal obesity could
be a risk factor for erosive esophagitis, independently of
BMI status (50-54). According to the meta-analysis by Cor-
ley et al., there was a significant relationship between BMI
status and GERD among the American population (over-
weight OR = 1.57, 95%CI = 1.36 - 1.80 and obese OR = 2.15, 95%CI
= 1.89 - 2.45), but not in Asian countries (55). One could
suggest that BMI was not a proper indicator for evaluat-
ing the percentage of body fat among Asian populations,
which might explain this conflicting result (56). Indeed, el-
evated BMI ranges are generally considered as overweight
or obesity and do not specify visceral fat or subcutaneous
fat (29). In particular, as visceral fat plays an important role
in the incidence of GERD, elevated BMI ranges without the
presence of visceral obesity will not definitely predict the
presence of GERD. Studies have shown that visceral obesity,
as the main criterion of MetS, could increase either tran-
sient lower esophageal sphincter (LES) relaxation, the in-
cidence of hiatal hernia, or even intra-abdominal pressure
and acid reflux (22, 57). Moreover, adipose tissue, especially
visceral adipocytes, is the major source of adiponectin and
pro-inflammatory cytokines such as interleukin (IL)-6 and
tumor necrosis factor (TNF)-α, which may play important
roles in the pathogenesis of GERD (20, 28, 58). It has been
shown that IL-6 decreases the contraction of the circular
muscles of the esophagus, which can facilitate the back-
ward flow of intragastric contents into the esophagus. In
addition, these cytokines were over-expressed in patients
with GERD, which might cause a disruption in insulin ac-
tion and might also stimulate the secretion of hepatic TG
(9, 29, 59). Consequently, insulin resistance can lead to
other metabolic disorders such as dyslipidemia and hyper-
glycemia that might play a role in GERD pathogenesis (60,
61).
Dyslipidemia, another component of MetS, can be as-
sociated with the development of GERD through disrupt-
ing the function of LES, which might cause an increase in
the esophagus’ exposure to gastric acid (43, 62, 63). Hyper-
glycemia may also affect the anti-reflux barrier mechanism
by modulating the transient LES relaxation (63). Hyper-
glycemia is usually accompanied by autonomic neuropa-
thy, which can delay gastric depletion and consequently
lead to the increased development of GERD (29, 34). More-
over, hypertension is usually diagnosed in patients with
MetS, and calcium antagonists are widely used to treat hy-
pertension in such patients. Hence, these calcium-based
medications may reduce the LES pressure and inhibit mus-
cle contraction in the esophagus (29). Above all, each
component of MetS can somehow affect the incidence of
GERD, indicating that the co-occurrence of three or more
of the five above-mentioned components might be associ-
ated with the incidence of GERD (28).
The main strength of the present systematic review
is the large sample sizes examined in the included stud-
ies. Also, in all of the studies, the existence of both GERD
and MetS was proven by established tests and evaluations
rather than relying on the previous registrations, which
might have contained errors. Additionally, we tried to per-
form a systematic and comprehensive search to identify
all the relevant published papers, which can lead to an ab-
sence of publication bias. However, this review has sev-
eral limitations. Meta-analysis statistical tests were not
performed in this study, which limited the potential to
identify more exact and definite results. Also, the de-
signs of all the included studies were either case-control
or cross-sectional, meaning that the results may not be
completely reliable. There might be several possible dis-
crepancies such as confounding variables, different meth-
ods of sampling or observation bias in these studies (64).
For instance, no adjustment was made for the amounts
of dietary components in the selected studies, which can
affect the development of GERD (65, 66). On the other
hand, despite the various adjustments for potential con-
founders, residual confounders related to other factors
might be associated with the incidence of GERD. Moreover,
it is difficult to specify the temporal sequence between ex-
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posure and outcome, since the assessments of MetS and
GERD were taken at exactly the same time, which provides
weaker evidence of causality than a cohort study. Hence,
cohort studies are better able to assess causality by evalu-
ating the exposure predicting outcomes (64, 67). Further
studies with a longitudinal design, including cohort stud-
ies, are hence needed to reach stronger conclusions.
In conclusion, it was shown that MetS and each com-
ponent of that condition, especially central obesity, can be
considered as independent risk factors for the incidence
of GERD, and they can be significantly associated with the
increased severity of erosive esophagitis. Therefore, since
MetS is a reliable predictive factor for the prevalence of
GERD, alleviating the metabolic abnormalities in patients
with GERD might cause significant potential benefits in the
treatment of GERD. Nonetheless, it is still unclear whether
these associations imply a causal relationship between
MetS and GERD. Hence, further studies with a longitudi-
nal design, including cohort studies and clinical trials, are
needed to reach stronger conclusions and better elucidate
these complexities.
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